Search This Blog

Thursday, January 9, 2020

Flexion sees Zilretta sales as high as $135M for 2020

On a preliminary basis, Flexion Therapeutics (NASDAQ:FLXN) expects Q4 and 2019 revenue to be $23.7M (+149%) and $73.0M (+224%), respectively.
2020 guidance: Zilretta sales: $120M – 135M.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)